Ethanol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ethanol: From Unspecified Original Use to Migraine Disorder
One-Sentence Summary
Ethanol (DB00898) has no documented original therapeutic indication in this evidence pack and is not currently marketed as a registered medicine in Australia. The TxGNN model predicts a strong knowledge-graph association with Migraine Disorder (99.29% score), but the supporting clinical trial and literature evidence indicates this association reflects ethanol’s role as a well-documented migraine trigger, not a treatment — this is a mechanistic red flag rather than a repurposing opportunity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified — no ARTG entry or original indication data available for ethanol in this evidence pack |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action data for ethanol was not available in this evidence pack (flagged as a High-severity data gap, DG002). However, the supporting literature does describe a clear pharmacological mechanism: ethanol is metabolised to acetaldehyde, which activates the TRPA1 ion channel and CGRP receptor pathway on trigeminal/meningeal Schwann cells and nociceptors (PMID 37101198) — the same CGRP/meningeal-nociceptor pathway implicated in migraine pain generation, including via ATP-sensitive potassium channel opening at meningeal nociceptors (PMID 40785517).
Critically, this mechanistic pathway runs in the opposite direction to what a repurposing candidate requires. Rather than relieving migraine, ethanol (alcohol) is one of the most consistently reported dietary/environmental trigger factors for migraine and other primary headache attacks — confirmed across a 2023 systematic review and meta-analysis (PMID 37612595), a 2025 narrative review (PMID 41305669), and multiple older reviews (PMID 18231712, PMID 36373782, PMID 8681169). The high TxGNN score (99.29%) most likely reflects the strength of the ethanol–migraine association in the underlying knowledge graph (co-occurrence as trigger/comorbidity), not a therapeutic relationship. No clinical trial identified in this evidence pack tests ethanol as a migraine treatment.
Clinical Trial Evidence
The search returned 32 trials on the query terms “Ethanol” + “migraine disorder,” but review of relevance grading found no trial that actually evaluates ethanol as a migraine treatment — all reviewed matches are keyword-search false positives (different active drug, or an unrelated disease/topic). The 10 graded trials are listed below for transparency:
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT05351086 | Phase 1 | Completed | 26 | Tests PUR3100, not ethanol — not relevant |
| NCT06508411 | N/A | Completed | 1661 | Observational study on pain and sexual health in cancer patients — unrelated to ethanol/migraine |
| NCT05175521 | N/A | Active, not recruiting | 50 | Tests inhaled isopropyl alcohol vapour (not ethanol) for migraine-associated nausea — drug mismatch |
| NCT02169830 | N/A | Terminated | 35 | Tests nortriptyline vs topiramate for vestibular migraine — unrelated to ethanol |
| NCT07297901 | N/A | Enrolling by invitation | 30 | App-based breathing/biofeedback programme — non-pharmacological, unrelated |
| NCT05685225 | Phase 2 | Withdrawn | 0 | Tests naltrexone/acetaminophen for acute migraine — unrelated to ethanol |
| NCT06476392 | Phase 3 | Active, not recruiting | 220 | Melatonin for chronic back pain — different disease, unrelated |
| NCT05266469 | N/A | Completed | 168 | Real-world cohort of ofatumumab/ocrelizumab in multiple sclerosis — unrelated keyword match |
| NCT06517446 | N/A | Recruiting | 48 | VR-based vestibular rehabilitation — non-pharmacological, unrelated |
| NCT06263920 | N/A | Recruiting | 360 | Late-onset epilepsy/stroke/dementia cohort — unrelated to ethanol treatment of migraine |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37612595 | 2023 | Systematic Review/Meta-analysis | J Headache Pain | Confirms alcohol is associated with increased risk of migraine and tension-type headache; migraine patients typically avoid alcohol as a trigger |
| 41305669 | 2025 | Review | Nutrients | Reviews alcohol as a headache trigger across migraine, tension-type headache and other primary headaches; mechanism remains incompletely defined |
| 36373782 | 2022 | Review | Headache | Describes the complex, bidirectional relationship between alcohol consumption and migraine |
| 18231712 | 2008 | Review | J Headache Pain | MEDLINE review finding ~1/3 of migraine patients report alcohol as a trigger, at least occasionally |
| 19486361 | 2010 | Case-control (genetic) | Headache | Alcohol dehydrogenase (ADH2) genotype investigated as a modifier of migraine risk from alcohol exposure |
| 37101198 | 2023 | Mechanistic/Animal | J Biomed Sci | Ethanol’s metabolite acetaldehyde activates CGRP receptor and TRPA1 on Schwann cells, driving periorbital allodynia relevant to migraine — a pro-migraine mechanism |
| 40785517 | 2025 | Mechanistic/Animal | Cephalalgia | KATP channel opening activates meningeal nociceptors, a proposed contributor to migraine headache origin |
| 35063053 | 2022 | Cohort | Aerosp Med Hum Perform | Cohort study of migraine outcomes in military pilots, assessing modifiable aggravating factors |
| 6352219 | 1983 | Mechanistic Review | Drug Alcohol Depend | Explores prostaglandin-mediated mechanisms of alcohol intolerance and hangover headache |
| 8681169 | 1996 | Review | Rev Neurol | Reviews dietary triggers of migraine, including alcohol-containing beverages |
Safety Considerations
No TGA-approved Product Information exists for ethanol as a registered medicine in Australia (0 ARTG entries; not marketed). Key warnings, contraindications, and drug–drug interaction data were not available in the sources queried (DrugBank, TGA/TFDA equivalents). Detailed regulatory safety data (TFDA label warnings/contraindications) is flagged as a Blocking data gap (DG001) and would need to be sourced before any safety assessment could proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic and clinical literature indicates ethanol is a documented trigger of migraine attacks (via acetaldehyde/CGRP/TRPA1 and meningeal nociceptor pathways), not a therapeutic agent — the opposite of what a repurposing candidate requires. No clinical trial evaluates ethanol as a migraine treatment, ethanol is not marketed as a medicine in Australia, and MOA/safety data are incomplete (one Blocking gap).
To proceed, the following is needed:
- Confirmation of whether the TxGNN association reflects a genuine therapeutic hypothesis or a trigger/comorbidity relationship, before any further clinical validation is considered
- TFDA/TGA-equivalent product warnings and contraindications (currently a Blocking data gap)
- Verified DrugBank mechanism-of-action data
- Given the directionally adverse mechanistic signal, this candidate is not recommended to advance past Hold without a substantive change in evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.